Amphastar Pharmaceuticals (AMPH)

Executive Summary

Amphastar Pharmaceuticals is a fully integrated biopharmaceutical company specializing in complex generic drugs, proprietary injectables, and biosimilars. With a market capitalization of approximately $900 million, the company leverages high-barrier-to-entry manufacturing capabilities across six U.S. facilities. Its portfolio includes the market-leading BAQSIMI® (nasal glucagon spray) for severe hypoglycemia and a pipeline of inhalation and injectable products targeting endocrinology, pulmonology, and nephrology. The company has completed several Phase 2/3 trials for asthma and diabetes products, positioning it for regulatory milestones. Amphastar's strategy focuses on developing therapeutic alternatives with proprietary delivery systems, driving growth through both organic pipeline advancements and strategic acquisitions. Despite competitive pressures in generics, Amphastar's differentiated product mix and robust manufacturing infrastructure support a resilient business model. Financially, Amphastar has demonstrated consistent revenue growth from its commercial portfolio, with BAQSIMI serving as a key growth driver. The company's near-term outlook is bolstered by pending ANDA submissions for high-value branded generics, including a potential generic version of liraglutide (Victoza) and an insulin glargine biosimilar. These approvals could significantly expand Amphastar's addressable market and drive earnings acceleration. Additionally, the company continues to invest in its proprietary inhalation and injectable platforms, which offer high barriers to competition. While generic market volatility and pricing pressures remain risks, Amphastar's focus on complex generics and biosimilars, combined with a strong balance sheet, positions it for sustained long-term value creation.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of ANDA for generic liraglutide (Victoza)70% success
• Q4 2026Launch of insulin glargine biosimilar following FDA approval65% success
• Q2 2026BAQSIMI sales growth update in next quarterly earnings (Q2 2026)80% success